Cambridge Cognition Partners with Ivory to Scale Early Cognitive Screening in India

Cambridge Cognition taps India’s brain health boom with Ivory partnership

Cambridge Cognition has signed a commercial agreement with Ivory to deploy its CANTAB Pathway cognitive assessments across India’s professional healthcare and consumer health markets. It is a strategic push into a huge, fast-growing territory where early cognitive screening is badly needed and digital health adoption is accelerating.

No financial terms, timelines, or exclusivity have been disclosed. Even so, the addressable market and product fit are clear, and that is why this update matters.

India’s brain health opportunity by the numbers

Total population	Approximately 1.47 billion
People aged over 60	138 million
Potentially living with mild or major cognitive impairment	Up to 34 million
Middle and affluent class	Estimated 90–190 million
Initial language coverage	English, Hindi, Tamil, Telugu, Bengali, Kannada
Target segments	Professional healthcare and consumer health

The LASI-DAD study cited in the RNS estimates up to 34 million older adults may be living with cognitive impairment in India. Multiple studies suggest that up to 90% of cases are underdiagnosed. That is the crux: scalable, validated screening tools could unlock earlier identification at population scale.

What Cambridge Cognition is selling into India

CANTAB Pathway is a tiered set of digital cognitive assessments designed for speed, ease of use and scientific rigour. The aim is objective results, low administrator burden, and suitability in both clinical settings and at home.

• CANTAB One – a brief assessment of overall cognitive function.
• CANTAB Insight – a three-task battery covering five cognitive sub-domains.
• CANTAB Plus – specialist, disease-specific modules for qualified healthcare professionals across eight indications including Parkinson’s disease, ADHD, multiple sclerosis, Huntington’s disease, schizophrenia, depression, and Alzheimer’s disease and related dementias.

Assessments deliver real-time or near-real-time results and are available in multiple Indian languages already, with more planned. That localisation piece is essential for scale in a multilingual country.

Why Ivory is a useful partner

Ivory is a venture-backed brain health company in India with a growing clinical network and a consumer-facing platform. The RNS notes Ivory offers an FDA-registered cognitive assessment within its app and is pushing proactive brain health through early detection and training programmes. It has public visibility and investor backing, and it recently published India’s first Brain Health Report.

In short, Ivory gives Cambridge Cognition distribution into both hospitals and clinics and into a health-conscious consumer base that is comfortable with digital monitoring and lifestyle tools. That dual-channel approach is a strong strategic match for CANTAB Pathway.

Why this update matters for investors

• Large unmet need – Underdiagnosis is high and there is no cure for many neurodegenerative conditions. Early screening is increasingly prioritised, which aligns with CANTAB Pathway’s design.
• Scalable product-market fit – Low-burden, validated digital tools with multilingual coverage fit India’s size, clinician constraints and consumer mobile adoption.
• International expansion – Management flags this as part of a broader push into high-growth international healthcare and consumer markets. India is one of the world’s most attractive test-beds for scale.

On balance, this reads positively for strategic execution. The absence of financial details tempers near-term modelling, but the direction of travel is clear – expand access, localise, and capture a share of a very large market across clinical and consumer channels.

Commercial shape and unanswered questions

Key commercial details are not disclosed in the RNS. That limits precision on potential revenue and timing, so here is what we do and do not know:

What’s stated

• Ivory intends to deploy CANTAB Pathway at scale across professional healthcare and consumer health segments in India.
• Cambridge Cognition’s assessments offer high accuracy, low administration burden and real-time results.
• Language availability includes English, Hindi, Tamil, Telugu, Bengali and Kannada, with further expansion planned.

Not disclosed

• Financial terms – upfront fees, minimums, revenue share, or pricing are not disclosed.
• Exclusivity – no statement on whether Ivory’s rights are exclusive by segment or region.
• Timelines and targets – no deployment milestones, user targets or site counts.
• Regulatory pathway in India – no detail on approvals or frameworks, if any are required for specific use cases.

How the product stack could play out in-market

Expect CANTAB One and Insight to be the entry points for quick, scalable screening in primary care, diagnostics, and consumer apps. CANTAB Plus is positioned for specialist clinics managing specific conditions where deeper, indication-focused assessments are warranted. The multilingual support should improve adoption rates across geographies and demographics inside India.

Risks and things to watch

• Execution risk – Scaling across two channels in a country of 1.47 billion requires strong operational follow-through.
• Clinical integration – Embedding routine screening in busy care pathways can be slow without aligned incentives.
• Unit economics – Without disclosed terms, it is unclear how quickly deployments translate to meaningful revenue.
• Local competition – Digital health in India is active; differentiation must remain clear on validation, accuracy and usability.

Management tone and scientific credibility

Both teams emphasise earlier identification and proactive brain health. Cambridge Cognition’s position rests on its scientific track record – thousands of peer-reviewed papers underpin CANTAB – and the product’s suitability for both clinical and consumer contexts. Ivory’s clinical team and public profile should help drive awareness and trust in-market.

What to look for next

• Deployment updates – number of sites, clinicians onboarded, and consumer uptake.
• Language and regional expansion – additional Indian languages and state-level rollouts.
• Partnership deals – tie-ups with hospital networks, diagnostics chains, and insurers.
• Evidence readouts – local validation studies or outcomes data demonstrating earlier detection at scale.
• Commercial clarity – any disclosure on pricing, revenue share, or exclusivity.

Josh’s take

This is a strategically smart move: large unmet need, validated product, and a partner with on-the-ground reach across both clinics and consumers. The multilingual support and low-burden, real-time assessments are well suited to India’s scale. The caveat is the usual one – without financials or milestones, the near-term revenue impact is hard to gauge. If Cambridge Cognition and Ivory show tangible deployment traction in the coming quarters, this could become a meaningful growth leg for the business.